Featured Products related products

Cat No.	Product Name	CAS No.	Product description
V52787	Carbazole-d8 (咔唑-d8)	38537-24-5	Carbazole-d8 is the deuterated form of Carbazole (HY-D0204).
V35046	Ditiocarb (Diethyldithiocarbamic acid)	147-84-2	Ditiocarb (Diethyldithiocarbamic acid) is a copper reagent that reacts with Cu2+ solution to form a complex, which increases the copper replacement precipitation rate.
V0300	Olaparib (AZD2281; KU0059436)	763113-22-0	Olaparib (formerly also known as AZD-2281; KU-59436; KU0059436; trade name Lynparza) is a potent,novel and orally bioavailable small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential anticancer activity.
V39377	DBCO-PEG3-TCO		DBCO-PEG3-TCO is a non-cleavable (non-degradable) ADC linker containing 3 Polyethylene glycol (PEG) units, which may be utilized to prepare Antibody-drug conjugates (ADC).
V0284	Sodium Phenylbutyrate (4-PBA sodium)	1716-12-7	Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium),an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS).
V0493	Foretinib (GSK-1363089; XL-880; EXEL2880; GSK-089)	849217-64-7	Foretinib (also known as GSK1363089; XL880; EXEL-2880; GSK089) is a novel, potent, ATP-competitive small-molecule inhibitor of multipletyrosine kinases (e.
V32889	DPN	1428-67-7	DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor ERβ selective ligand with EC50 of 0.85 nM.
V0611	AZD3463	1356962-20-3	AZD-3463 (AZD3463) is a novel, potent and selective ALK/IGF1R inhibitor with potential anticancer activity.
V0630	Pexidartinib (PLX3397; Turalio; CML261; FP113)	1029044-16-3	Pexidartinib (formerly PLX-3397; CML-261;FP-113; trade name Turalio) is an orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor of CSF-1R, Kit, and Flt3 with potential antineoplastic activity.
V0633	GW2580 (SC203877)	870483-87-7	GW2580 (also known as SC-203877)is a novel, potent, selective, and orally bioavailable c-Fms kinaseCSF-1R inhibitor with potential antineoplastic activity.
V19288	DCKA	131123-76-7	5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective NMDA receptor glycine site competitive antagonist (inhibitor) with a Kb of 65 nM.
V0001	Venetoclax (ABT-199; GDC-0199)	1257044-40-8	Venetoclax (formerly known as ABT-199 or GDC-0199; Venclexta) is a potent, selective andorally bioavailablesmall molecule inhibitor of theanti-apoptotic protein BCL-2 (B-cell lymphoma-2) with Ki of<0.01 nM.
V47750	15-Nor-14-oxolabda-8(17),12E-Diene-18-oic acid	1039673-32-9	15-Nor-14-oxolabda-8(17),12E-Diene-18-oic acid (compound 9) is a compound extracted from Chloranthus spicatus.
V30349	Echinocystic acid	510-30-5	Echinocystic acid is a naturally occurringpentacyclic triterpene found in the fruits of Gleditsia sinensis Lam with antioxidant, anti-inflammatory and anticancer pactivities.
V20571	Enmenol	28957-06-4	Enmenol is a novel and potent bioactive compound
V0245	Acadesine (AICAR; NSC-105823)	2627-69-2	Acadesine (also known as NSC105823,AICA-riboside, and AICAR) is a novel and potent AMPK (AMP-activated protein kinase) activatorwith potential antitumor and antidiabetic activity.
V0342	Tofacitinib (CP690550; tasocitinib)	477600-75-2	Tofacitinib (also known as tasocitinib or CP-690550, sold under the brandXeljanz),is a novel and potent inhibitor of JAK3 (Janus-Associated kinase) with potential anti-inflammatory activity.
V51454	KRA-533	10161-87-2	KRA-533 is a selective KRAS agonist.
V0075	AZD1390	2089288-03-7	AZD1390 (AZD-1390) is a novel, potent, selective, first-in-class orally bioavailable and CNS penetrant inhibitor of Ataxia-telangiectasia mutated (ATM) kinase with potential anticancer activity.
V0725	Telaprevir ( LY-570310; VX950; MP-424)	402957-28-2	Telaprevir (also known as LY570310; VX-950; MP424; trade names: Incivek; Incivo), a marketed medication for HCV treatment, is a selective, and reversible peptidomimetic inhibitor of HCV NS3-4A serine protease with an IC50 of 0.35 μM.